Can Drug Repositioning Work as a Systematical Business Model?
Related Experiment Video
Updated: Aug 11, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou ZJ571, China.
Abstract:
As a business model, drug repositioning is facing increasing challenges from both academia and industry. To examine the feasibility of drug repositioning as a systematical business model, a drug revenue formula is introduced. By breaking down key factors into indication, price, patient population, and market share, the potentiality of the drug repositioing business model is confirmed. In addition, some unworkable repositioning stratgies are also summarized.
Related Concept Videos
Drug Discovery: Overview
Prodrugs
Prodrugs help overcome...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

